Insulin Glargine/Lixisenatide FRC Trial Targets Superior HbA1c vs. GLP-1 RA in Type 2 Diabetes
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Abstract
A clinical trial is designed to compare the efficacy and safety of insulin glargine/lixisenatide FRC against GLP-1 RAs for HbA1c reduction in Type 2 Diabetes patients.